Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

768
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
768
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

451
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
451
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

932
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
932
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

1.1K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.1K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

746
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
746
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

539
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
539

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Guideline-Directed Medical Therapy Use and Dose Optimization after TAVR in Patients with Persistent HFrEF.

Journal of cardiac failure·2026
Same author

Pregnancy Management and Outcomes with Hypertrophic Cardiomyopathy.

CJC open·2026
Same author

Chimeric antigen receptor T-cell therapy and cardiovascular outcomes in US Medicare beneficiaries.

European heart journal·2026
Same author

Baroreflex Activation Therapy In Heart Failure-the Barostim-Enabled Neurohormonal Intervention for Improving Treatment of Heart Failure (BENEFIT-HF) Trial Rationale and Design.

Journal of cardiac failure·2026
Same author

Recent updates in the management of atrial fibrillation in patients with cardiac amyloidosis.

Future cardiology·2026
Same author

Preservation Strategy and Sex-Specific Risk of Severe Primary Graft Dysfunction After Heart Transplantation: A GUARDIAN-Heart Analysis.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2026

Related Experiment Video

Updated: Sep 26, 2025

The Intra-Aortic Balloon Pump
06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

22.3K

Beta-blockers and Ambulatory Inotropic Therapy.

Raja Zaghlol1, Amre Ghazzal1, Sohab Radwan1

  • 1From the Division of Internal Medicine, Georgetown/Medstar Washington Hospital Center, Washington, D.C.

Journal of Cardiac Failure
|April 21, 2022
PubMed
Summary

For advanced heart failure patients on ambulatory inotropic therapy (AIT), combining beta-blockers (BB) with inotropes significantly reduced heart failure hospitalizations and ventricular arrhythmias. This combination therapy improves outcomes in this high-risk population.

Keywords:
Milrinonearrhythmiasbeta-blockersinotropes

More Related Videos

Contractility Measurements on Isolated Papillary Muscles for the Investigation of Cardiac Inotropy in Mice
06:22

Contractility Measurements on Isolated Papillary Muscles for the Investigation of Cardiac Inotropy in Mice

Published on: September 17, 2015

15.1K
Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation
08:56

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation

Published on: September 24, 2021

2.8K

Related Experiment Videos

Last Updated: Sep 26, 2025

The Intra-Aortic Balloon Pump
06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

22.3K
Contractility Measurements on Isolated Papillary Muscles for the Investigation of Cardiac Inotropy in Mice
06:22

Contractility Measurements on Isolated Papillary Muscles for the Investigation of Cardiac Inotropy in Mice

Published on: September 17, 2015

15.1K
Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation
08:56

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation

Published on: September 24, 2021

2.8K

Area of Science:

  • Cardiology
  • Pharmacology
  • Critical Care Medicine

Background:

  • Ambulatory inotropic therapy (AIT) is increasingly utilized for end-stage heart failure (HF).
  • Limited data exists on the concurrent use of beta-blockers (BB) with AIT in HF patients.
  • This study investigates the impact of BB use in patients receiving AIT.

Purpose of the Study:

  • To evaluate the safety and efficacy of concomitant beta-blocker (BB) use in patients with end-stage heart failure (HF) receiving ambulatory inotropic therapy (AIT).
  • To compare outcomes, including hospitalizations and arrhythmias, between patients on AIT with and without BBs.

Main Methods:

  • Retrospective review of patients discharged on AIT between 2010 and 2017.
  • Stratification into two groups: those receiving BBs and those not.
  • Comparison of hospitalization rates for HF, ventricular arrhythmias, and ICD therapies between groups.

Main Results:

  • 56% of 349 AIT patients received BBs; 44% did not.
  • The BB group experienced significantly lower rates of HF hospitalizations (HR 0.61), ventricular arrhythmias (HR 0.34), and ICD therapies (HR 0.24) after adjustment.
  • Patients on BBs also had a longer duration of AIT support.

Conclusions:

  • Concomitant use of beta-blockers (BB) with inotropes in end-stage heart failure (HF) patients on ambulatory inotropic therapy (AIT) is associated with improved outcomes.
  • This combination therapy demonstrates a significant reduction in heart failure hospitalizations and ventricular arrhythmias.
  • BBs may be safely integrated with AIT to enhance patient management and reduce adverse events.